Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Webinar: Raising the bar for patients with HR+/HER2- early breast cancer

Aired live on 25 May 2022


ESMO Webinar: Raising the bar for patients with HR+/HER2- early breast cancer

Chair: Sibylle Loibl
Speakers: Evandro De Azambuja, Stephen Johnston, Shaheenah Dawood


Login to get immediate access to this content.


ESMO Members take the CME test

and receive 1 ESMO - MORA point

Learning objectives

  • To increase knowledge on risk assessment and rational application of adjuvant strategies in patients with early luminal HER2- breast cancer
  • To provide up to date information on the value of CDK4/6 inhibitors in adjuvant management of these patients as well as highlight ongoing research
  • To emphasise the value of multidisciplinary assessment of patients with early breast cancer in the personalised medicine era

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.